Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AJMUC1 in advanced MUC1-positive breast cancer
NCT05812326Phase 2Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2019
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AJMUC1 in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Number of participants with adverse events and dose limiting toxicities at 3 years, Incidence of treatment-emergent adverse events at 3 years and 1 more. Started May 2019; status: completed.
02
Drugs
AJMUC1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05812326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812326.